Abstract
Seventy-nine patients with AML in CR1 received allo-SCT between May 2006 and May 2011, and the prognostic impact of FMS-like tyrosine kinase 3/internal tandem duplication (FLT3/ITD) mutation was evaluated in the context of other clinical prognostic factors. Patients with FLT3/ITD+ AML had significantly inferior DFS (2-year DFS: 19% vs 64%, P=0.0027), increased risk of relapse (1-year: 59% vs 19%, P=0.01), and a trend towards decreased OS (P=0.08) compared with patients without FLT3/ITD. Multivariate analysis confirmed FLT3/ITD+ independently predicted a shorter DFS (HR, 3.0; 95% CI), 1.4–6.5; P=0.01) and increased risk of relapse (HR, 4.9; 95% CI, 2.0–12.3, P=0.01). Time to relapse in patients with FLT3/ITD+ was short with 100-day cumulative risk of 45% (95% CI, 33–57). Our data suggest that the poor prognostic implication of FLT3/ITD positivity remains even after early allo-SCT in patients with FLT3/ITD+ AML, and patients remain at high risk of early relapse. FLT3/ITD positivity also outweighs other conventional prognostic markers in predicting relapse.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326–4335.
Savani BN . Transplantation in AML CR1. Blood 2010; 116: 1822–1823.
Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002; 100: 4372–4380.
Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T . Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia 2005; 19: 1345–1349.
Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909–1918.
Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911–1918.
Bornhauser M, Illmer T, Schaich M, Soucek S, Ehninger G, Thiede C . Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood 2007; 109: 2264–2265.
Meshinchi S, Arceci RJ, Sanders JE, Smith FO, Woods WB, Radich JP et al. Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. Blood 2006; 108: 400–401.
DeZern AE, Sung A, Kim S, Smith BD, Karp JE, Gore SD et al. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant 2011; 17: 1404–1409.
Yoshimoto G, Nagafuji K, Miyamoto T, Kinukawa N, Takase K, Eto T et al. FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2005; 36: 977–983.
Bacher U, Haferlach C, Schnittger S, Kern W, Kroeger N, Zander AR et al. Interactive diagnostics in the indication to allogeneic SCT in AML. Bone Marrow Transplant 2009; 43: 745–756.
Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074–3080.
Savani BN, Mielke S, Reddy N, Goodman S, Jagasia M, Rezvani K . Management of relapse after allo-SCT for AML and the role of second transplantation. Bone Marrow Transplant 2009; 44: 769–777.
Pavletic SZ, Kumar S, Mohty M, de LM, Foran JM, Pasquini M et al. NCI First International Workshop on the Biology. Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant 2010; 16: 871–890.
Levis M . FLT3/ITD AML and the law of unintended consequences. Blood 2011; 117: 6987–6990.
Alatrash G, de LM, Hamerschlak N, Pelosini M, Wang X, Xiao L et al. Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant 2011; 17: 1490–1496.
Yokoyama H, Lundqvist A, Su S, Childs R . Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation. Blood 2010; 116: 2858–2859.
Kruger WH, Hirt C, Kiefer T, Neumann T, Busemann C, Dolken G . Molecular remission of FLT3-ITD(+) positive AML relapse after allo-SCT by acute GVHD in addition to sorafenib. Bone Marrow Transplant 2011; 47: 137–138.
Chiusolo P, Metafuni E, Bellesi S, Giammarco S, Za T, Laurenti L et al. Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia. Bone Marrow Transplant 2012; 47: 872–873.
Rezvani K . Posttransplantation vaccination: concepts today and on the horizon. Hematology. Am Soc Hematol Educ Program 2011; 2011: 299–304.
Acknowledgements
We would like to thank Janice Tracy for her contribution to this project.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Sengsayadeth, S., Jagasia, M., Engelhardt, B. et al. Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers. Bone Marrow Transplant 47, 1535–1537 (2012). https://doi.org/10.1038/bmt.2012.88
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2012.88
Keywords
This article is cited by
-
A comparative study of next-generation sequencing and fragment analysis for the detection and allelic ratio determination of FLT3 internal tandem duplication
Diagnostic Pathology (2022)
-
Adverse impact of a high allelic burden FLT3-ITD mutation on allogeneic hematopoietic stem cell transplantation in patients with cytogenetically normal AML
International Journal of Hematology (2022)
-
Advances in targeted therapy for acute myeloid leukemia
Biomarker Research (2020)
-
Current Approaches to Transplantation for FLT3-ITD AML
Current Hematologic Malignancy Reports (2020)
-
FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients
Bone Marrow Transplantation (2019)